151751-Najiba-Chargi

CHAPTER 13 The predictive value of low skeletal muscle mass assessed on cross-sectional imaging for anti-cancer drug toxicity: a systematic review and meta-analysis 235 CHAPTER 14 The association of cisplatin pharmacokinetics and skeletal muscle mass in head and neck cancer: the prospective PLATISMA study 257 CHAPTER 15 Patterns, predictors and prognostic value of skeletal muscle mass loss in patients with locally advanced head and neck cancer undergoing cisplatin- based chemoradiotherapy 273 CHAPTER 16 Skeletal muscle mass is an imaging biomarker for decreased survival in patients with oropharyngeal squamous cell carcinoma 293 CHAPTER 17 Dysphagia, trismus and speech impairment following radiation-based treat- ment for advanced stage oropharyngeal carcinoma: a one-year prospective evaluation 313 PART IV SARCOPENIA IN ELDERLY HEAD AND NECK CANCER PATIENTS CHAPTER 18 Sarcopenia is a prognostic factor for overall survival in elderly patients with head and neck cancer 361 CHAPTER 19 Sarcopenia measured with handgrip strength and skeletal muscle mass to assess frailty in older patients with head and neck cancer 381 CHAPTER 20 Low skeletal muscle mass predicts frailty in elderly head and neck cancer patients 401 CHAPTER 21 Summarizing discussion General discussion and future perspectives 421 CHAPTER 22 Nederlandse samenvatting 440 About the author 451 Dankwoord 452